ClinicaliQ Trial Snapshot
- A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight — Recruiting • Phase III • Oncology • NCT07232719.
- The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits. Lead.
- Sponsor: Eli Lilly and Company.
Verify eligibility, endpoints and current status on the original source registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits. Lead Sponsor: Eli Lilly and Company Start Date: 2025-11-17 Primary Completion: 2027-07
Eligibility Snapshot
- : * Have a body mass index (BMI) of: * ≥30 kilogram per square meter (kg/m2) OR * ≥27 kg/m2 with at least one of the following weight-related conditions: high blood pressure, abnormal levels of lipid, obstructive sleep apnea, heart disease * Have at least one unsuccessful attempt to lose weight by dieting
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.